These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27934319)

  • 41. Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents.
    Ludwig G; Kaluđerović GN; Rüffer T; Bette M; Korb M; Block M; Paschke R; Lang H; Steinborn D
    Dalton Trans; 2013 Mar; 42(11):3771-4. PubMed ID: 23340605
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
    Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
    Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
    Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
    J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ruthenium-arene complexes of curcumin: X-ray and density functional theory structure, synthesis, and spectroscopic characterization, in vitro antitumor activity, and DNA docking studies of (p-cymene)Ru(curcuminato)chloro.
    Caruso F; Rossi M; Benson A; Opazo C; Freedman D; Monti E; Gariboldi MB; Shaulky J; Marchetti F; Pettinari R; Pettinari C
    J Med Chem; 2012 Feb; 55(3):1072-81. PubMed ID: 22204522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties.
    Pelletier F; Comte V; Massard A; Wenzel M; Toulot S; Richard P; Picquet M; Le Gendre P; Zava O; Edafe F; Casini A; Dyson PJ
    J Med Chem; 2010 Oct; 53(19):6923-33. PubMed ID: 20822096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reversible pH-Responsive Behavior of Ruthenium(II) Arene Complexes with Tethered Carboxylate.
    Martínez-Peña F; Infante-Tadeo S; Habtemariam A; Pizarro AM
    Inorg Chem; 2018 May; 57(9):5657-5668. PubMed ID: 29688005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(ii) terpyridine complexes.
    Lazić D; Arsenijević A; Puchta R; Bugarčić ŽD; Rilak A
    Dalton Trans; 2016 Mar; 45(11):4633-46. PubMed ID: 26855406
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Highly active neutral ruthenium(II) arene complexes: synthesis, characterization, and investigation of their anticancer properties.
    Ludwig G; Kaluđerović GN; Bette M; Block M; Paschke R; Steinborn D
    J Inorg Biochem; 2012 Aug; 113():77-82. PubMed ID: 22698819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
    Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
    Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New ruthenium(II) arene complexes of anthracenyl-appended diazacycloalkanes: effect of ligand intercalation and hydrophobicity on DNA and protein binding and cleavage and cytotoxicity.
    Ganeshpandian M; Loganathan R; Suresh E; Riyasdeen A; Akbarsha MA; Palaniandavar M
    Dalton Trans; 2014 Jan; 43(3):1203-19. PubMed ID: 24177707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Studies on anticancer properties with varying co-ligands in a Ru(II) arene benzimidazole system.
    Pragti ; Nayek S; Singh S; Sonawane A; Grabchev I; Ganguly R; Mukhopadhyay S
    Dalton Trans; 2023 May; 52(21):7104-7118. PubMed ID: 37158792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fine tuning through valence bond tautomerization of ancillary ligands in ruthenium(ii) arene complexes for better anticancer activity and enzyme inhibition properties.
    Mandal P; Malviya N; Guedes da Silva MF; Dhankhar SS; Nagaraja CM; Mobin SM; Mukhopadhyay S
    Dalton Trans; 2016 Dec; 45(48):19277-19289. PubMed ID: 27868122
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experimental and theoretical investigations of cyclometalated ruthenium(ii) complex containing CCC-pincer and anti-inflammatory drugs as ligands: synthesis, characterization, inhibition of cyclooxygenase and in vitro cytotoxicity activities in various cancer cell lines.
    Tabrizi L; Olasunkanmi LO; Fadare OA
    Dalton Trans; 2019 Jan; 48(2):728-740. PubMed ID: 30560261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anticancer and antibacterial potential of robust Ruthenium(II) arene complexes regulated by choice of α-diimine and halide ligands.
    Zanda E; Busto N; Biancalana L; Zacchini S; Biver T; Garcia B; Marchetti F
    Chem Biol Interact; 2021 Aug; 344():109522. PubMed ID: 34029541
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent and selective anticancer activity of half-sandwich ruthenium and osmium complexes with modified curcuminoid ligands.
    Pagliaricci N; Pettinari R; Marchetti F; Pettinari C; Cappellacci L; Tombesi A; Cuccioloni M; Hadiji M; Dyson PJ
    Dalton Trans; 2022 Sep; 51(35):13311-13321. PubMed ID: 35983757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
    Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
    J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
    Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
    J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of PPh₃ moiety in the anticancer activity of new organometallic ruthenium complexes.
    Sáez R; Lorenzo J; Prieto MJ; Font-Bardia M; Calvet T; Omeñaca N; Vilaseca M; Moreno V
    J Inorg Biochem; 2014 Jul; 136():1-12. PubMed ID: 24690555
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β-Diketonates.
    Seršen S; Kljun J; Kryeziu K; Panchuk R; Alte B; Körner W; Heffeter P; Berger W; Turel I
    J Med Chem; 2015 May; 58(9):3984-96. PubMed ID: 25856666
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The synthesis, lipophilicity and cytotoxic effects of new ruthenium(II) arene complexes with chromone derivatives.
    Pastuszko A; Majchrzak K; Czyz M; Kupcewicz B; Budzisz E
    J Inorg Biochem; 2016 Jun; 159():133-41. PubMed ID: 26986980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.